1. Musib L, Kowanetz M, Li Q, et al. Furmonertinib is an oral, irreversible, highly brain-penetrant pan-EGFR mutant inhibitor with activity against classical and atypical EGFR mutations. Presented at the North American Conference in Lung Cancer; September 2022. 2. Robichaux JP, Le X, Vijayan RSK, et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021;597(7878):732-737.
The FURTHER study
Now enrolling:
Research for patients with advanced or metastatic non-small cell lung cancer (NSCLC) with uncommon EGFR mutations
Patients with uncommon EGFR mutations have limited treatment options
There are no clear established guidelines for the treatment of NSCLC patients with uncommon EGFR mutations outside of exon 20 insertion, S768I, and G719X mutations (NCCN 2023).
●
Mutational activation of epidermal growth factor receptor (EGFR) is a common and early development event in NSCLC; it creates oncogene dependency for proliferation and survival of the cancer cell.
EGFR-mutation-positive NSCLC can be divided into “classical” activating EGFR mutations (exon 19 deletions and L858R point mutation) and “uncommon” EGFR activating mutations. Uncommon EGFR mutations account for approximately 30% of all EGFR mutations. (Robichaux et al, 2021). Patients with NSCLC whose tumors harbor uncommon EGFR mutations face limited treatment options and have significantly lower life expectancy.
There is a critical need for effective and tolerable therapies in NSCLC with uncommon EGFR mutations.
The FURTHER study is investigating furmonertinib as an investigational drug in adults with advanced or metastatic NSCLC harboring uncommon EGFR mutations.
Furmonertinib is:
●
Designed to be an oral, brain-penetrant inhibitor of classical and uncommon EGFR mutations
●
Approved in China for the treatment of adult patients with previously treated locally advanced or metastatic NSCLC with EGFR T790M mutations and for the first‑line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) mutations.
The FURTHER study is:
●
Phase 1b, open label, and multicenter
●
Currently enrolling patients with uncommon EGFR mutations
References:
Download and share the study brochure with your patients.
Who can participate in this study?
Patients who meet the following criteria may qualify:
●
≥ 18 years of age
●
Histologically or cytologically documented, locally advanced, or metastatic NSCLC not amenable to curative surgery or radiotherapy.
●
Previously untreated in the locally advanced or metastatic setting or have progressed after at least 1 available standard therapy, or for whom standard therapy has proven to be ineffective, intolerable, or considered inappropriate.
●
Documented radiologic disease progression during or after the last systemic anti-cancer therapy before the first dose of furmonertinib.
●
Documented validated results from local testing of either tumor tissue or blood performed at a CLIA- or equivalently certified laboratory confirming the presence of an EGFR uncommon mutation.
Eligible mutations include, but are not limited to:
G719X, S768I, E709X, G779F, L747X, V774M, E709_T710delinsD, R776C/H, G724S, E736K, I740_K745dup, N771G, K757M/R, V769L/M, T854X, T751_I759del insN
This is not a full list of criteria. Please use the contact form to receive more information about the study eligibility criteria.
Study Summary
Study Drug:
Furmonertinib,
administered orally
administered orally
Study Objective:
The primary objective is to evaluate the safety and tolerability of furmonertinib administered daily to patients with locally advanced or metastatic NSCLC with uncommon EGFR mutations
Participant Details:
18+
with advanced or metastatic NSCLC
with advanced or metastatic NSCLC
Sponsor:
ArriVent
Enrollment Period:
Currently enrolling
Site Locations
Click on the map below to see study site locations near you.
Patients may be reimbursed for costs to travel to and from study sites.
Location
Click to copy and paste nearby study site locations into your patient notes.
© 2023 ArriVent Biopharma. All Rights Reserved.